Targeting Factor XI for Safer Anticoagulation: Emerging Data and Future Directions.

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Hematology

Background:

• Direct oral anticoagulants (DOACs) present challenges in balancing bleeding risk and efficacy.
• Factor XI (FXI) is a key target for novel anticoagulants due to its role in thrombosis and limited contribution to hemostasis.

Purpose of the Study:

• To review the biological rationale for targeting FXI/FXIa.
• To summarize pharmacological features of FXI inhibitors.
• To discuss clinical trial results and future directions for FXI inhibitors.

Main Methods:

• Review of biological rationale for FXI inhibition.
• Summary of pharmacological profiles of FXI inhibitor classes (ASOs, mAbs, small molecules).
• Analysis of Phase I-II trial data and ongoing Phase III programs.

Main Results:

• FXI inhibition demonstrates robust efficacy in preventing venous thromboembolism post-orthopedic surgery.
• Efficacy in atrial fibrillation and secondary stroke prevention has shown variable results.
• Early studies confirm FXI inhibitors' potential for antithrombotic protection with reduced bleeding.

Conclusions:

• FXI inhibitors offer a promising therapeutic strategy for antithrombotic protection with a potentially lower bleeding risk.
• Further research is needed to define optimal indications, patient selection, and positioning relative to DOACs.
• Uncertainties remain for high-bleeding-risk populations and specific thrombotic conditions.